Home
Kyverna Therapeutics

Kyverna Therapeutics Market Share Analysis for June 2026

Watch these videos to expand your knowledge about CAR T-cell therapies and autoimmune diseases from scientist and patient perspectives.

Health > Biotechnology and Pharmaceuticals

Domainkyvernatx.com

Year Founded2018

Employees51 - 200

Annual Revenue--

Kyverna Therapeutics

Kyverna Therapeutics (including company regionals)

kyvernatx.com

See more website traffic and engagement information

Total visits to Kyverna Therapeutics's top domains

Understand Kyverna Therapeutics market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

kyvernatx.com12.8K

See more with Sales Intelligence

Avg. visit duration in Kyverna Therapeutics's top domains

Analyze Kyverna Therapeutics engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

kyvernatx.com00:01:51

See more with Sales Intelligence

Avg. pageviews on Kyverna Therapeutics's top domains

See how Kyverna Therapeutics keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

kyvernatx.com3.25

See more with Sales Intelligence

Kyverna Therapeutics top competitors by domain

Top similar sites in June 2026, ranked by their affinity

tnrbiofab.comCompany NameT&R BiofabEmployees51 - 200HQKorea, Republic of, SiheungodongAnnual revenue$5M - $10MTotal visits1KHealth > Medicine

Top technologies used by Kyverna Therapeutics

These are the website technologies, by industry, used by Kyverna Therapeutics top domains

Widget (3)

Twemoji

Advertising (2)

DoubleClick

Audio Video Media (2)

YouTube

Conversion & Analytics (2)

Google Analytics

More Technologies

10

See all

News & Signals from Kyverna Therapeutics

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsKyverna Therapeutics, Inc. identified as competitor of Vertex Pharmaceuticals on Jan 1st '26.Kyverna Therapeutics vs. Vertex Pharmaceuticals: which drug developer stock is a better buy in 2026?

NewsKyverna Therapeutics, Inc. attends event EULAR 2026.Kyverna Therapeutics' CD19-directed CAR T therapy, mivocabtagene autoleucel (miv-cel; KYV-101), delivered deep B-cell depletion, sustained autoantibody suppression, and durable clinical benefit in refractory rheumatoid arthritis, with updated Phase 1 COMPARE trial results presented at EULAR 2026.